Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | TSHR | P16473 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2826616 | 0.93 | POLB (0.42) | KMT2ATSHRMEN1SMN1; SMN2LMNA | |
| SCHEMBL2827742 | 0.85 | GAA (0.50) | KMT2ATSHRMEN1SMN1; SMN2LMNA | |
| SCHEMBL2827476 | 0.85 | KMT2A (0.46) | KMT2ATSHRMEN1SMN1; SMN2LMNA | |
| SCHEMBL2827849 | 0.82 | KMT2A (0.61) | KMT2ATSHRMEN1SMN1; SMN2LMNA | |
| SCHEMBL2827876 | 0.81 | POLB (0.49) | KMT2ATSHRMEN1SMN1; SMN2LMNA | |
| SCHEMBL2829280 | 0.81 | PIM1 (0.46) | KMT2ATSHRMEN1SMN1; SMN2LMNA | |
| SCHEMBL2828886 | 0.81 | SMN1; SMN2 (0.51) | KMT2ATSHRMEN1SMN1; SMN2LMNA | |
| SCHEMBL2825500 | 0.81 | ALDH1A1 (0.48) | KMT2ATSHRMEN1SMN1; SMN2LMNA | |
| SCHEMBL2829677 | 0.80 | POLB (0.51) | KMT2ATSHRMEN1SMN1; SMN2LMNA | |
| SCHEMBL2829178 | 0.79 | ALDH1A1 (0.52) | KMT2ATSHRMEN1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948648-B1 | 3-ARYL-ISOXAZOLE-4-CARBONYL-BENZOFURANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-05-05 | — | — | EP | claimed |
| EP-1948648-A2 | 3-ARYL-ISOXAZOLE-4-CARBONYL-BENZOFURAN DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-30 | — | — | EP | claimed |
| US-7388025-B2 | 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-06-17 | — | — | US | claimed |
| WO-2007054444-A2 | 3-ARYL-ISOXAZOLE-4-CARBONYL-BENZOFURAN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-18 | — | — | WO | claimed |
| US-20070105922-A1 | 3-aryl-isoxazole-4-carbonyl-indole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-10 | — | — | US | claimed |
| EP-1948648-B1 | 3-ARYL-ISOXAZOLE-4-CARBONYL-BENZOFURANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-05-05 | — | — | EP | disclosed |
| EP-1948648-A2 | 3-ARYL-ISOXAZOLE-4-CARBONYL-BENZOFURAN DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-30 | — | — | EP | disclosed |
| US-7388025-B2 | 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-06-17 | — | — | US | disclosed |
| WO-2007054444-A2 | 3-ARYL-ISOXAZOLE-4-CARBONYL-BENZOFURAN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105922-A1 | 3-aryl-isoxazole-4-carbonyl-indole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105922-A1 | 3-aryl-isoxazole-4-carbonyl-indole derivatives | GABRA5, GABRA4, GABRA3 | KMT2A 2367/4885TSHR 840/4885MEN1 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.